CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Follow-on public offering	HK IPO	Collaboration revenue	Adjustment to opening balance of equity	Adjusted Balance	Total	Total Follow-on public offering	Total HK IPO	Total Collaboration revenue	Total Adjustment to opening balance of equity	Total Adjusted Balance	Ordinary Shares	Ordinary Shares Follow-on public offering	Ordinary Shares HK IPO	Ordinary Shares Collaboration revenue	Ordinary Shares Adjusted Balance	Additional Paid-In Capital	Additional Paid-In Capital Follow-on public offering	Additional Paid-In Capital HK IPO	Additional Paid-In Capital Collaboration revenue	Additional Paid-In Capital Adjusted Balance	Accumulated Other Comprehensive Income/(Loss)	Accumulated Other Comprehensive Income/(Loss) Adjustment to opening balance of equity	Accumulated Other Comprehensive Income/(Loss) Adjusted Balance	Accumulated Deficit	Accumulated Deficit Adjustment to opening balance of equity	Accumulated Deficit Adjusted Balance	Non- Controlling Interests	Non- Controlling Interests Adjustment to opening balance of equity	Non- Controlling Interests Adjusted Balance
Balance at the beginning of period at Dec. 31, 2017	$ 684,231				$ (2,291)	$ 681,940	$ 669,809				$ (2,666)	$ 667,143	$ 59				$ 59	$ 1,000,747				$ 1,000,747	$ (480)	$ 263	$ (217)	$ (330,517)	$ (2,929)	$ (333,446)	$ 14,422	$ 375	$ 14,797
Balance at the beginning of period (in shares) at Dec. 31, 2017													592,072,330				592,072,330
Increase (Decrease) in Stockholders' Equity
Issuance of ordinary shares in connection		$ 757,587	$ 869,709					$ 757,587	$ 869,709					$ 10	$ 7				$ 757,577	$ 869,702
Issuance of ordinary shares in connection (in shares)														102,970,400	65,600,000
Use of shares reserved for share option exercises and RSU releases (in shares)													1,299,186
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	87,127						87,127											87,127
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	29,662						29,662						$ 1					29,661
bgne_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans													14,321,268
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest																													(88)
Other comprehensive income/(loss)							1,743																1,743
Other comprehensive income/(loss)	1,655
Net Income (Loss) Attributable to Noncontrolling Interest	(264)																												(264)
Net loss attributable to BeiGene, Ltd.	(673,769)						(673,769)																			(673,769)
Net loss	(674,033)
Balance at the ending of period at Dec. 31, 2018	1,753,647						1,739,202						$ 77					2,744,814					1,526			(1,007,215)			14,445
Balance at the ending of period (in shares) at Dec. 31, 2018													776,263,184
Increase (Decrease) in Stockholders' Equity
Contributions from shareholders	4,000																												4,000
Exercise of options, ESPP and release of RSUs (in shares)													20,571,675
Use of shares reserved for share option exercises and RSU releases (in shares)													4,505,839
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	134,154						134,154											134,154
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	47,004						47,004						$ 2					47,002
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent							(9,527)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest																													(345)
Other comprehensive income/(loss)																							(9,527)
Other comprehensive income/(loss)	(9,872)																						(9,527)
Net Income (Loss) Attributable to Noncontrolling Interest	(1,950)																												(1,950)
Net loss attributable to BeiGene, Ltd.	(948,628)						(948,628)																			(948,628)
Net loss	(950,578)
Balance at the ending of period at Dec. 31, 2019	$ 978,355						962,205						$ 79					2,925,970					(8,001)			(1,955,843)			16,150
Balance at the ending of period (in shares) at Dec. 31, 2019	801,340,698												801,340,698
Increase (Decrease) in Stockholders' Equity
Issuance of ordinary shares in connection	$ 2,069,610			$ 2,162,407			2,069,610			$ 2,162,407			$ 14			$ 21		2,069,596			$ 2,162,386
Issuance of ordinary shares in connection (in shares)													145,838,979			206,635,013
Exercise of options, ESPP and release of RSUs (in shares)													38,020,892
Use of shares reserved for share option exercises and RSU releases	1						1						$ 1
Use of shares reserved for share option exercises and RSU releases (in shares)													(1,013,641)
APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition							183,481
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	183,481																	183,481
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	93,101						93,101						$ 3					93,098
Deconsolidation of a subsidiary	(3,545)																												(3,545)
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	28,715																												9,116
Acquisition of joint venture ("JV") minority interest							(19,599)											(19,599)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest																													128
Other comprehensive income/(loss)							14,943																14,943
Other comprehensive income/(loss)	15,071																						14,943
Net Income (Loss) Attributable to Noncontrolling Interest	(3,617)																												(3,617)
Net loss attributable to BeiGene, Ltd.	(1,596,906)						(1,596,906)																			(1,596,906)
Net loss	(1,600,523)
Balance at the ending of period at Dec. 31, 2020	$ 3,869,243						$ 3,869,243						$ 118					$ 7,414,932					$ 6,942			$ (3,552,749)			$ 0
Balance at the ending of period (in shares) at Dec. 31, 2020	1,190,821,941												1,190,821,941